10x Genomics Inc [TXG] stock is trading at $9.34, up 5.36%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TXG shares have gain 12.20% over the last week, with a monthly amount glided 11.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
10x Genomics Inc [NASDAQ: TXG] stock has seen the most recent analyst activity on February 13, 2025, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $12 from $25. Previously, Leerink Partners started tracking the stock with Outperform rating on September 03, 2024, and set its price target to $35. On July 22, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $24 on the stock. JP Morgan downgraded its rating to a Neutral and decreased its price target to $20 on July 18, 2024. Deutsche Bank downgraded its rating to a Hold and reduced its price target to $25 on July 10, 2024. Wolfe Research downgraded its rating to Peer Perform for this stock on June 27, 2024. In a note dated June 25, 2024, Guggenheim downgraded an Neutral rating on this stock.
10x Genomics Inc [TXG] stock has fluctuated between $6.78 and $24.76 over the past year. Currently, Wall Street analysts expect the stock to reach $30.2 within the next 12 months. 10x Genomics Inc [NASDAQ: TXG] shares were valued at $9.34 at the most recent close of the market. An investor can expect a potential return of 223.34% based on the average TXG price forecast.
Analyzing the TXG fundamentals
10x Genomics Inc [NASDAQ:TXG] reported sales of 624.66M for the trailing twelve months, which represents a growth of 9.84%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.25%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.22 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.97 points at the first support level, and at 8.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.55, and for the 2nd resistance point, it is at 9.76.
Ratios To Look Out For
For context, 10x Genomics Inc’s Current Ratio is 5.37. Also, the Quick Ratio is 4.68, while the Cash Ratio stands at 3.49. Considering the valuation of this stock, the price to sales ratio is 1.87, the price to book ratio is 1.63.
Transactions by insiders
Recent insider trading involved Saxonov Serge, Chief Executive Officer, that happened on May 22 ’25 when 9343.0 shares were sold., Hindson Benjamin J. completed a deal on May 22 ’25 to sell 7485.0 shares. Meanwhile, Chief Financial Officer Taich Adam sold 4044.0 shares on May 22 ’25.
